4541.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 kov. 2023 @ 09:15):

Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group...

Stats
Šios dienos apimtis	5.21M
Vidutinė apimtis	4.06M
Rinkos kapitalizacija	2.47B
EPS	¥0 ( 2023-05-11 )
Last Dividend	¥10.00 ( 2022-03-30 )
Next Dividend	¥0 ( N/A )
P/E	0.0000000
ATR14	¥4.97 (0.00%)

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: -0.73 (moderate negative)

Signal:(100) Neutral

Nichi-Iko Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Nichi-Iko Pharmaceutical Koreliacija - Valiuta/Žaliavos

0.01
( neutral )

0.09
( neutral )

0.05
( neutral )

0.18
( neutral )

0.42
( neutral )

-0.11
( neutral )

Nichi-Iko Pharmaceutical Finansinės ataskaitos

Annual	2022
Pajamos:	¥16 907.73B
Bruto pelnas:	¥3 331.59B (19.70 %)
EPS:	¥128.01

FY	2022
Pajamos:	¥16 907.73B
Bruto pelnas:	¥3 331.59B (19.70 %)
EPS:	¥128.01

FY	2022
Pajamos:	¥179.06B
Bruto pelnas:	¥3.97B (2.21 %)
EPS:	¥-1 500.00

FY	2021
Pajamos:	¥188.22B
Bruto pelnas:	¥21.25B (11.29 %)
EPS:	¥-65.28

Financial Reports:

No articles found.

Nichi-Iko Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Nichi-Iko Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.48 - good (94.76%) | Divividend Growth Potential Score: 2.02 - No dividend growth expected in the near future

Information

First Dividend	¥12.00	2008-05-27
Last Dividend	¥10.00	2022-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	29	--
Total Paid Out	¥380.90	--
Avg. Dividend % Per Year	0.00%	--
Score	3.01	--
Div. Sustainability Score	9.48
Div.Growth Potential Score	2.02
Div. Directional Score	5.75	--

Next Divdend (Est)
(2024-06-10)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.01

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6866.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
6238.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4963.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
4118.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3349.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
2427.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9364.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8056.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7309.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
6555.T	Ex Dividend Junior	2024-02-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0400	1.500	9.20	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0137	1.200	9.54	10.00	[0 - 0.3]
returnOnEquityTTM	0.0717	1.500	-0.315	-0.472	[0.1 - 1]
payoutRatioTTM	0.555	-1.000	4.45	-4.45	[0 - 1]
currentRatioTTM	1.440	0.800	7.80	6.24	[1 - 3]
quickRatioTTM	0.617	0.800	-1.074	-0.859	[0.8 - 2.5]
cashRatioTTM	0.584	1.500	7.86	10.00	[0.2 - 2]
debtRatioTTM	0.185	-1.500	6.92	-10.00	[0 - 0.6]
interestCoverageTTM	92.82	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	119.18	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	86.82	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.474	-1.500	8.11	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.202	1.000	9.97	9.97	[0.2 - 0.8]
operatingProfitMarginTTM	0.0414	1.000	-1.172	-1.172	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.121	1.000	-0.438	-0.438	[0.2 - 2]
assetTurnoverTTM	0.344	0.800	-1.042	-0.833	[0.5 - 2]
Total Score				9.48

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.478	1.000	-0.0527	0	[1 - 100]
returnOnEquityTTM	0.0717	2.50	-0.202	-0.472	[0.1 - 1.5]
freeCashFlowPerShareTTM	86.82	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	119.18	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.555	1.500	4.45	-4.45	[0 - 1]
pegRatioTTM	-0.000222	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0651	1.000	-0.872	0	[0.1 - 0.5]
Total Score				2.02

Nichi-Iko Pharmaceutical

Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.